华北制药(600812.SH):阿莫西林胶囊及头孢氨苄胶囊拟中标全国药品集中采购
格隆汇1月19日丨华北制药(600812.SH)公告,2020年1月17日,华北制药股份有限公司(以下简称“公司”)及下属子公司华北制药河北华民药业有限责任公司(以下简称“华民公司”)参加了联合采购办公室组织的全国药品集中采购(采购文件编号:GY-YD2019-2)工作。
公司已获得国家药品监督管理局仿制药质量和疗效一致性评价的仿制药品阿莫西林胶囊(250mg、500mg)、下属子公司华民公司已获得国家药品监督管理局仿制药质量和疗效一致性评价的仿制药品头孢氨苄胶囊(250mg)拟中标本次集中采购。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.